Jefferies Downgrades AstraZeneca (AZN) to Underperform
Tweet
Share
E-mail
Get Alerts AZN Hot Sheet
Price: $92.77 --0%
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 4
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 4
Join SI Premium – FREE
Jefferies downgraded AstraZeneca (NYSE: AZN) from Hold to Underperform and cut its price target from 2,900p to 2,600p.
The firm notes, "our estimates are materially below consensus, driven by our bearish view on Crestor, Brilinta and margins during our forecast period."
For more ratings news on AstraZeneca click here and for the rating history of AstraZeneca click here.
Shares of AstraZeneca closed at $51.63 yesterday.
The firm notes, "our estimates are materially below consensus, driven by our bearish view on Crestor, Brilinta and margins during our forecast period."
For more ratings news on AstraZeneca click here and for the rating history of AstraZeneca click here.
Shares of AstraZeneca closed at $51.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
- Goldman Sachs Downgrades China Telecom (728:HK) (CHA) to Sell
- Goldman Sachs Downgrades China Tower Corp Ltd. (788:HK) (CHWRF) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
